GCM
FOLD

Graham Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Graham Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,685
Closed -$556K – 1105
2023
Q3 		$556K Buy
+45,685
New +$589K 0.01% 531

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Graham Capital Management's FOLD Position: Q4 2023 in Review

Graham Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2023, closing a stake of 45,685 shares — an estimated $556K sold.

Graham Capital Management first reported a position in FOLD in Q3 2023 and held it in 1 quarter. The position peaked at $556K in Q3 2023. 228 funds tracked by Wall St. Rank hold FOLD as of Q4 2023.

  • Graham Capital Management reported no remaining Amicus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Graham Capital Management sold 45,685 Amicus Therapeutics shares in Q4 2023, an estimated $556K.
  • Graham Capital Management first reported a position in Amicus Therapeutics in Q3 2023 and held it in 1 quarter.
  • Graham Capital Management's Amicus Therapeutics position peaked at $556K in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2023.

Based on Graham Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.